Literature DB >> 9385488

The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion.

R A Blum1, H Shi, M D Karol, P A Greski-Rose, R H Hunt.   

Abstract

The effects on 24-hour intragastric pH levels of once-daily doses of lansoprazole 15 mg and lansoprazole 30 mg were compared with the effects of omeprazole 20 mg QD and ranitidine 150 mg QID in a phase I, randomized, double-masked, four-way crossover study conducted in 29 healthy male volunteers. Subjects received each treatment regimen for 5 consecutive days with at least a 2-week washout between treatment periods. Ambulatory 24-hour intragastric pH values were monitored in each subject at baseline (2 days before crossover period 1) and again before dosing on day 5 of each of the four crossover treatment periods. Gastric pH values increased during all four regimens, with significantly higher mean 24-hour pH values noted in subjects receiving lansoprazole 30 mg QD (4.53 +/- 0.16) compared with those receiving lansoprazole 15 mg QD (3.97 +/- 0.16), omeprazole 20 mg QD (4.02 +/- 0.16), or ranitidine 150 mg QID (3.59 +/- 0.16). Lansoprazole 30 mg produced significantly greater mean percentages of time that the gastric pH was above 3.0 and 4.0 (75% and 63%, respectively) compared with the other treatment regimens. The mean percentages of time during which gastric pH was above 3.0 and 4.0, respectively, for the other treatments were lansoprazole 15 mg, 64% and 48%; omeprazole 20 mg, 63% and 51%; and ranitidine 150 mg, 52% and 38%. All treatment regimens were well tolerated, with no clinically significant differences between the regimens. Multiple-dose lansoprazole 30 mg QD produced a significantly increased intragastric pH level and significantly longer durations of increased intragastric pH level compared with lansoprazole 15 mg QD, omeprazole 20 mg QD, and ranitidine 150 mg QID.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9385488     DOI: 10.1016/s0149-2918(97)80053-7

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  17 in total

Review 1.  What is potent acid inhibition, and how can it be achieved?

Authors:  Xavier Calvet; Fernando Gomollón
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Head-to-head comparison of H2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis.

Authors:  Wei-Hong Wang; Jia-Qing Huang; Ge-Fan Zheng; Harry Hua-Xiang Xia; Wai-Man Wong; Shiu-Kum Lam; Benjamin Chun-Yu Wong
Journal:  World J Gastroenterol       Date:  2005-07-14       Impact factor: 5.742

Review 3.  Lansoprazole: an update of its place in the management of acid-related disorders.

Authors:  A J Matheson; B Jarvis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  The impact of reflux composition on mucosal injury and esophageal function.

Authors:  Daniel S Oh; Jeffrey A Hagen; Martin Fein; Cedric G Bremner; Christy M Dunst; Steven R Demeester; John Lipham; Tom R Demeester
Journal:  J Gastrointest Surg       Date:  2006-06       Impact factor: 3.452

5.  Comparing the acid-suppressive effects of three brands of generic lansoprazole with the original: pharmacokinetic bioequivalence tests do not necessarily guarantee pharmacodynamic equivalence.

Authors:  Tomohiko Shimatani; Seiko Hirokawa; Yumiko Tawara; Kazuko Hamai; Mutsuko Matsumoto; Susumu Tazuma; Masaki Inoue
Journal:  Dig Dis Sci       Date:  2008-12-18       Impact factor: 3.199

6.  Gastroesophageal reflux in children: pathogenesis, prevalence, diagnosis, and role of proton pump inhibitors in treatment.

Authors:  Benjamin D Gold; James W Freston
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 7.  Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug.

Authors:  Mary Beth Wire; Mark J Shelton; Scott Studenberg
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

8.  A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteers.

Authors:  Monika Schöller-Gyüre; Thomas N Kakuda; Goedele De Smedt; Hilde Vanaken; Marie-Paule Bouche; Monika Peeters; Brian Woodfall; Richard M W Hoetelmans
Journal:  Br J Clin Pharmacol       Date:  2008-04-25       Impact factor: 4.335

Review 9.  Lansoprazole: in the management of gastroesophageal reflux disease in children.

Authors:  Lesley J Scott
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 10.  Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH.

Authors:  Julia Kirchheiner; Silke Glatt; Uwe Fuhr; Ulrich Klotz; Ingolf Meineke; Thomas Seufferlein; Jürgen Brockmöller
Journal:  Eur J Clin Pharmacol       Date:  2008-10-17       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.